MediciNova, Inc. (MNOV) Gains 17.52% in one Year: What’s Next?

MediciNova, Inc. (NASDAQ:MNOV) went down by -33.09% from its latest closing price when compared to the 1-year high value of $13.25 and move down -80.03%, while MNOV stocks collected 87.39% of gains with the last five trading sessions. Press Release reported on 07/27/20 that MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan

>> Stay Up To Date On The Best Stocks Under $5 + Market Moving Updates 100% Free. Join Today! <<

MediciNova, Inc. (NASDAQ:MNOV) Worth an Investment?

MediciNova, Inc. (NASDAQ: MNOV) The 36 Months beta value for MNOV stocks is at 1.72, while 3 of the analysts out of 3 who provided ratings for MediciNova, Inc. stocks as a “buy” while 0 as overweight, 0 rated it as hold and 0 as sell. The average price we get from analysts is $18.73 which is -$7.36 below current price. MNOV currently has a short float of 6.04% and public float of 39.57M with average trading volume of 1.43M shares.

MNOV Market Performance

MNOV stocks went up by 87.39% for the week, with the monthly jump of 94.35% and a quarterly performance of 98.56%, while its annual performance rate touched 17.52%. The simple moving average for the period of the last 20 days is 25.08% for MNOV stocks with the simple moving average of 23.42% for the last 200 days.

Analysts’ Opinion on MediciNova, Inc. (NASDAQ:MNOV)

Many brokerage firms have already submitted their reports for MNOV stocks, with B. Riley FBR repeating the rating for MNOV shares by setting it to “Buy”. The predicted price for MNOV socks in the upcoming period according to B. Riley FBR is $22 based on the research report published on March 25, 2019.

B. Riley FBR, Inc., on the other hand, stated in their research note that they expect to see MNOV stock at the price of $22. The rating they have provided for MNOV stocks is “Buy” according to the report published on March 28, 2018.

Credit Suisse gave “Outperform” rating to MNOV stocks, setting the target price at $22 in the report published on April 18, 2017.

MNOV Stocks 30.34% Far from 50 Day Moving Average

After a stumble in the market that brought MNOV to its low price for the period of the last 52 weeks, MediciNova, Inc. was unable to take a rebound, for now settling with -44.45% of loss for the given period.

The stock volatility was left at 9.75%, however, within the period of a single month, the volatility rate increased by 23.96%, while the shares surge at the distance of +37.32% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +34.84% upper at the present time.

In the course of the last 5 trading sessions, MNOV went up by +29.46%, which changed the moving average for the period of 200 days to the total of +1.49% of gains for the stock in comparison to the 20-day moving average settled at $5.99. In addition, MediciNova, Inc. saw 63.20% in overturn over the period of a single year with a tendency to cut further gains.

MNOV Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at MediciNova, Inc. (MNOV), starting from Matsuda Kazuko, who bought 2,000 shares at the price of $3.62 back on Mar 13. After this action, Rushing now owns 111,476 shares of MediciNova, Inc., valued at $7,240 with the latest closing price.

IWAKI YUICHI, the President and CEO of MediciNova, Inc., bought 20,000 shares at the value of $3.10 during a trade that took place back on Mar 12, which means that IWAKI YUICHI is holding 780,683 shares at the value of $62,000 based on the most recent closing price.

MNOV Stock Fundamentals

Based on MediciNova, Inc. (MNOV), the company’s capital structure generated 0.53 points for debt to equity in total, while total debt to capital is set at the value of 0.53.

Related Articles

Daily High to Daily Low: Is It Safe to Buy Forterra, Inc. (FRTA)?

Forterra, Inc. (NASDAQ:FRTA) went down by -4.27% from its latest closing price compared to the recent 1-year high of $17.58. The company’s stock price...

We Analyzed the Future Direction of Humanigen, Inc. (HGEN), Here is What We Found

Humanigen, Inc. (NASDAQ:HGEN) went up by 13.83% from its latest closing price compared to the recent 1-year high of $33.95. The company’s stock price...

Can Hoth Therapeutics, Inc. (HOTH) Remain Competitive?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) went up by 1.28% from its latest closing price compared to the recent 1-year high of $7.25. The company’s stock...

Latest Posts

Daily High to Daily Low: Is It Safe to Buy Forterra, Inc. (FRTA)?

Forterra, Inc. (NASDAQ:FRTA) went down by -4.27% from its latest closing price compared to the recent 1-year high of $17.58. The company’s stock price...

We Analyzed the Future Direction of Humanigen, Inc. (HGEN), Here is What We Found

Humanigen, Inc. (NASDAQ:HGEN) went up by 13.83% from its latest closing price compared to the recent 1-year high of $33.95. The company’s stock price...

Can Hoth Therapeutics, Inc. (HOTH) Remain Competitive?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) went up by 1.28% from its latest closing price compared to the recent 1-year high of $7.25. The company’s stock...

Is There a Dimmer Outlook Ahead for Cubic Corporation?

Cubic Corporation (NYSE:CUB) went up by 24.66% from its latest closing price compared to the recent 1-year high of $75.20. The company’s stock price...

Legend Biotech Corporation (LEGN): Skating on Thin Ice? We Know the Answer

Legend Biotech Corporation (NASDAQ:LEGN) went down by -17.72% from its latest closing price compared to the recent 1-year high of $43.24. The company’s stock...